文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

动脉粥样硬化性血脂异常与糖尿病肾病。

Atherogenic dyslipidemia and diabetic nephropathy.

机构信息

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo Della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo, FG, Italy.

出版信息

J Nephrol. 2020 Oct;33(5):1001-1008. doi: 10.1007/s40620-020-00739-8. Epub 2020 Apr 23.


DOI:10.1007/s40620-020-00739-8
PMID:32328901
Abstract

Chronic kidney disease is associated with altered lipid metabolism and lipid accumulation. Although it is though that hyperlipemia is a consequence of kidney dysfunction, several lines of evidence support that hyperlipidemia may contribute to the onset and progression of kidney disease, also in diabetes. This review describes the results of recent observational studies supporting the concept that glucose is only partly responsible for kidney damage onset, while a cluster of factors, including hypertriglyceridemia and low HDL-cholesterol, could play a relevant role in inducing onset and progression of DKD. We also report the results of randomized clinical trials investigating in type 2 diabetic patients the role of drug improvement of hypertriglyceridemia on renal outcomes. Finally, we discuss putative mechanisms linking hyperlipidemia (i.e. hypertriglyceridemia or low HDL cholesterol) with kidney disease.

摘要

慢性肾脏病与脂质代谢紊乱和脂质堆积有关。虽然高脂血症被认为是肾功能障碍的结果,但有几条证据支持高脂血症可能导致肾脏疾病的发生和进展,在糖尿病中也是如此。这篇综述描述了支持以下观点的最新观察性研究结果,即葡萄糖只是导致肾脏损伤发生的部分原因,而包括高三酰甘油血症和低高密度脂蛋白胆固醇在内的一组因素可能在诱导 DKD 的发生和进展中发挥重要作用。我们还报告了在 2 型糖尿病患者中研究药物改善高三酰甘油血症对肾脏结局影响的随机临床试验结果。最后,我们讨论了将高脂血症(即高三酰甘油血症或低高密度脂蛋白胆固醇)与肾脏疾病联系起来的潜在机制。

相似文献

[1]
Atherogenic dyslipidemia and diabetic nephropathy.

J Nephrol. 2020-10

[2]
Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative.

Diabetes Care. 2016-10-4

[3]
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Am J Cardiovasc Drugs. 2005

[4]
Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.

Curr Opin Endocrinol Diabetes Obes. 2018-4

[5]
Vascular inflammation, atherosclerosis, and lipid metabolism and the occurrence of non-high albuminuria diabetic kidney disease: A cross-sectional study.

Diab Vasc Dis Res. 2021

[6]
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.

BMC Cardiovasc Disord. 2017-6-17

[7]
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.

Cardiovasc Diabetol. 2021-4-30

[8]
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Cardiovasc Diabetol. 2010-6-15

[9]
Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population.

Lipids Health Dis. 2018-9-5

[10]
[Diabetic dyslipidaemia and the atherosclerosis].

Orv Hetil. 2016-5-8

引用本文的文献

[1]
Exploring the Incidence and Risk Factors of Diabetic Nephropathy in Type 1 Diabetes: Insights from a Retrospective Cohort Study in Northwest China.

Diabetes Metab Syndr Obes. 2025-7-8

[2]
Prevalence and risk factors of diabetic nephropathy among type 2 diabetes patients in family medicine clinic AFHSR Khamis Mushait.

J Family Med Prim Care. 2025-5

[3]
Sex-specific and metabolic subgroup heterogeneity in high-density lipoprotein cholesterol associations with diabetic kidney disease risk: a retrospective cohort study.

Lipids Health Dis. 2025-6-7

[4]
Therapeutic role of Crateva religiosa in diabetic nephropathy: Insights into key signaling pathways.

PLoS One. 2025-5-28

[5]
Association between serum spexin levels and diabetic nephropathy in patients with type 2 diabetes: a cross-sectional study.

Int Urol Nephrol. 2025-5-10

[6]
The association between the cardiac metabolic index and rapid kidney function decline and CKD in individuals with different glucose metabolism statuses: results from the China health and retirement longitudinal study.

Lipids Health Dis. 2025-4-23

[7]
Lipid abnormality in diabetic kidney disease and potential treatment advancements.

Front Endocrinol (Lausanne). 2025-3-18

[8]
Association between cardiometabolic index and albuminuria: Evidence from NHANES 2017-2020.

PLoS One. 2025-2-25

[9]
Exercise as a therapeutic approach to alleviate diabetic kidney disease: mechanisms, clinical evidence and potential exercise prescriptions.

Front Med (Lausanne). 2024-10-25

[10]
Targeting lncRNA MALAT1: A Promising Approach to Overcome Metabolic Syndrome.

Int J Endocrinol. 2024-10-28

本文引用的文献

[1]
Pathophysiology of Diabetic Dyslipidemia.

J Atheroscler Thromb. 2018-7-12

[2]
Glucose control and vascular complications in veterans with type 2 diabetes.

N Engl J Med. 2009-1-8

[3]
Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases.

Kidney Int. 1993-4

[4]
The Sustaining Fantasy Questionnaire: measurement of sustaining functions of fantasies in psychiatric inpatients.

J Pers Assess. 1983-8

[5]
The future of cybernation in health testing laboratories.

Med Instrum. 1974

[6]
Histology of infection by Pseudomonas lachrymans.

Phytopathology. 1967-3

[7]
Salbutamol and quinterenol: dipsogenic action produced by beta-adrenergic stimulants.

Pharmacol Biochem Behav. 1974-5

[8]
[Gastroresistant varnishing with aqueous solutions of cellulose acetate phthalate].

Boll Chim Farm. 1985-6

[9]
Evidence for an essential arginine residue in the active site of Escherichia coli 2-keto-4-hydroxyglutarate aldolase. Modification with 1,2-cyclohexanedione.

J Biol Chem. 1985-5-10

[10]
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.

J Med Chem. 1987-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索